AI-Powered Disease Management Platform Jianhai Tech Secures RMB 60 Million in Series A3 Funding Led by Source Code Capital

VCBeat learned that in September 2020, Hangzhou Jianhai Science and Technology Co., Ltd. (hereinafter referred to as “Jianhai Tech”), a well-known AI disease management platform in China, completed its RMB 60 million Series A3 financing round,This round of financing was led by Source Code Capital, with Sherpa Capital participating as a co-investor. Probes Capital served as the exclusive financial advisor for the third time.Since 2020, Hangzhou Jianhai Science and Technology Co., Ltd. has secured two rounds of financing, totaling over RMB 100 million. Wang Jian, CEO of Jianhai Tech, stated thatThis round of financing will continue to be used for the in-depth development of AI-powered full-course disease management solutions, accelerating the exploration of clinical scenarios and validation of efficacy for specific diseases, as well as expediting specialty-specific deployment and research capabilities.

(Jianhai Technology Financing Table)

Founded in 2015, Jianhai Technology is one of the few innovative modern enterprises in the industry capable of focusing on the post-hospital market and providing comprehensive AI-driven whole-course disease management solutions.

Committed to becoming China’s largest third-party disease management service platform, Jianhai Technology has achieved rapid development in the few short years since its establishment,Not only has it pioneered the core AI technology of the “Jishi Brain,” achieving closed-loop smart management for patients from hospitals to communities and then to their homes; it has also launched the “AI Full-Course Disease Management Platform” for hospitals, the “AI Tiered Diagnosis and Treatment Platform for Chronic Diseases” for medical consortia/health consortia, and industry-first “Third-Party Full-Course Disease Management Services,” truly realizing people-centric, holistic, and end-to-end health management.

Based on these innovative technologies and products, Jianhai Technology has gained significant market recognition. Currently, it serves more than 400 hospitals at the Grade II Class A level or above.

Regarding the next phase of plans, Wang Jian, CEO of Hangzhou Jianhai Science and Technology Co., Ltd., stated that under the new economic policy landscape in the post-pandemic era, national investment in the field of public health is expected to remain robust, while public demand for personal health management and post-hospitalization services will continue to rise.

Jianhai Technology will continue to increase R&D investment and strengthen product development capabilities in follow-up care, chronic disease management, third-party medical service management, and AI technology.Meanwhile, the addition of Source Code Capital as an investor, coupled with the continued support from existing shareholder Sherpa Partners, will further strengthen the company’s efforts to standardize management and ensure financial compliance, thereby preparing it for entry into the capital markets.

Regarding this financing round, Sun Tong from Source Code Capital, the lead investor, stated: “Jianhai Technology is one of the few companies in China that has achieved genuine implementation of artificial intelligence in the healthcare sector. Its products have been adopted by hundreds of tertiary hospitals. By leveraging a disease knowledge graph refined over many years and combining it with an AI-based semantic recognition system, the company has significantly improved the efficiency of doctors and nurses. In the management and treatment of certain diseases, Jianhai is already exploring the use of AI. Source Code Capital firmly believes that information technology will transform and elevate China’s healthcare industry. We are committed to supporting Jianhai’s long-term development and look forward to continuing to identify other outstanding entrepreneurial ventures.”

Source Code Capital was founded in the spring of 2014, dedicated to identifying and empowering leading enterprises in the wave of the information revolution. The firm currently manages $1.5 billion and RMB 5 billion. The entrusted capital primarily comes from top-tier global institutions and industrial investors, including sovereign wealth funds, university endowments, charitable foundations, pension funds, funds of funds, family offices, and industry-leading corporations, as well as national-level guidance funds and large central state-owned enterprises. Adhering to first-principles thinking and deep research-driven investment strategies, Source Code Capital has invested in nearly 150 companies along the three major thematic lines of “Internet+,” “Intelligence+,” and “Global+” within its “Three Horizontal, Nine Vertical” investment framework. These investments span major sectors such as media and content, consumer services, industrial enterprises, finance, retail, automotive and real estate, and education and healthcare.

Sherpa Investment was established in 2018, focusing on healthcare projects in China or closely related to local Chinese applications with high growth potential, including but not limited to pharmaceuticals, medical devices, services, and internet and technology solutions related to healthcare. Sherpa Investment is a professional healthcare investment fund whose core team members have worked together for many years, possessing extensive investment experience and an outstanding track record in China’s healthcare industry. The team is committed to being the climbers behind the climbers, empowering entrepreneurs to reach the pinnacle of their careers.